Back to today’s briefing

Story perspectives

Moderna’s mRNA Vaccine Shows Promise Amid Approval Delays

5/11/2025

28 4

Summary

Story summary

Moderna's innovative mRNA-1083 vaccine is making waves, demonstrating equal or superior protection against both flu and COVID-19 in a Phase III trial involving 8,000 participants. While the results are promising, recent FDA policy shifts could postpone its approval, possibly delaying its availability until 2026 or beyond.

1 of 1

Story summary

Moderna's innovative mRNA-1083 vaccine is making waves, demonstrating equal or superior protection against both flu and COVID-19 in a Phase III trial involving 8,000 participants. While the results are promising, recent FDA policy shifts could postpone its approval, possibly delaying its availability until 2026 or beyond.